A Systematic Review on the Safety and Efficacy of COVID-19 Vaccines Approved in Saudi Arabia

Author:

Alhandod Thekra Ali1,Rabbani Syed Imam1ORCID,Almuqbil Mansour2,Alshehri Sultan3,Hussain Syed Arif4,Alomar Nasser Fawzan5,Mir Manzoor Ahmad6,Asdaq Syed Mohammed Basheeruddin7ORCID

Affiliation:

1. Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia

2. Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

3. Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh 13713, Saudi Arabia

4. Respiratory Care Department, College of Applied Sciences, Almaarefa University, Riyadh 13713, Saudi Arabia

5. Equame Scientific and Research Center, Riyadh 13713, Saudi Arabia

6. Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar 190006, India

7. Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Riyadh 13713, Saudi Arabia

Abstract

Comprehensive safety and efficacy studies of COVID-19 vaccines might reduce the apprehension of the general population about the adverse reactions and duration of protection offered by them. The study aimed to conduct a systemic review on the four COVID-19 vaccines (AstraZeneca, Pfizer, Moderna, and Janssen) approved in Saudi Arabia. The study was conducted by reviewing the published articles from electronic databases such as PubMed, Embase, Cochrane Library and Web of Science using the search terms “COVID-19”, “Vaccine”, “Safety”, “Efficacy” and “Human trials” and as per the standard guidelines for systemic review. The review analyzed eighteen articles and the data from them were evaluated to analyze the safety and efficacy of the vaccines in different groups of population such as males, females, those above 18 years and people with co-morbidities. The common local reactions observed after vaccination were pain at the site of injection (40–70%), redness (16–30%), swelling (18–39%) and tenderness (20–40%). The systemic reactions reported were fever (40–60%), chills (12–23%), fatigue (44–65%), headache (30–42%) and muscle pain (15–40%). The efficacy was observed to be above the threshold value (60%) stipulated by the WHO. However, precautions need to be followed while vaccinating special groups of population such as those that are pregnant, lactating or experiencing severe illness. Additionally, the rare and serious adverse events reported remotely after vaccination need more studies.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference45 articles.

1. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study;Shi;Lancet Infect. Dis.,2020

2. The outbreak of COVID-19 coronavirus and its impact on global mental health;Torales;Int. J. Soc. Psychiat.,2020

3. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19);Sanders;JAMA,2020

4. COVID-19, Vaccine Development to Vaccination;Pandey;J. Nepal Health Res. Council.,2021

5. Vaccine safety issues at the turn of the 21st century;Conklin;BMJ Glob. Health,2021

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3